Key messages:
- d3 Medicine and Viroclinics Biosciences believe strongly that the traditional model for development companies engaging CROs and consultants can be improved.
- CROs are usually engaged on an arms-length basis
- d3 Medicine and Viroclinics believe that optimal use of their combined expertise is realize when they are integrated into project teams rather than providing ad hoc arms-length advice around particular problems without hearing the views of the overall client project team and their external key advisors.
- d3 Medicine believes that there is great value in being able to offer our clients access to Viroclinics virology expertise which spans from early development through to post-marketing commitments and their external key advisors .
- Viroclinics believes that by working with d3 Medicine it can now offer its clients access to expertise in clinical pharmacology and clinical development to design innovative and adaptive drug development plans for both biologics and small molecule antiviral drugs which leverage data provided by Viroclinics virology services.
- Delivers more robust data packages to inform development strategies and provide valuable data to support both pricing and reimbursement negotiations and commercial transactions.
Strategic alliance to provide services from virology assay development and testing to formulation of accelerated clinical development plans for drugs, biologicals, vaccines and diagnostics.
Parsippany, New Jersey, United States
and Rotterdam, the Netherlands
– 1st of July 2014 –
d3 Medicine LLC, an expert biopharmaceutical strategic advisory company, and Viroclinics Biosciences BV, a virology service organization, announced today that they have signed a non-exclusive Memorandum of Understanding to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical development of drugs, biologicals, vaccines and diagnostics targeting viral infectious diseases.
The alliance leverages the strengths of the two companies and will offer services that enable biopharmaceutical customers to accelerate virological investigational agents through preclinical and clinical development to market launch. Viroclinics Biosciences will provide a range of preclinical and clinical diagnostic services, including high throughput serology, virology and molecular assays, phenotyping and genotyping in both translational studies and phase I-IV clinical studies, and clinical trial logistics services. d3 Medicine will formulate integrated development, clinical pharmacology and translational medicine strategies to fast-track preclinical development and define customised pharmacometric and quantitative pharmacological approaches to improve decision making and accelerate clinical and regulatory development.
“Biopharmaceutical companies now can turn to d3 Medicine and Viroclinics Biosciences to develop and implement their preclinical, clinical and regulatory strategies when developing therapeutics, vaccines and diagnostics for viral infectious diseases,” said Dr Craig Rayner, CEO and co-Founder of d3 Medicine.
“We are delighted to be able to work more formally with the team at d3 Medicine,” said Dr Bob van Gemen, CEO of Viroclinics Biosciences. “They have great credibility in the market and when combined with the unique virology capabilities and expertise of Viroclinics Biosciences, we believe that through our partnership we offer customers the most comprehensive and exciting range of development services available in the virology field. We can support our biopharmaceutical customers with the best virological knowledge available and provide them with integrated and optimally customised development programs and project solutions.”
About d3 Medicine LLC
d3 Medicine is a biopharmaceutical drug development strategic advisory company founded by a group of pharmaceutical company executives with decades of drug development experience. d3 Medicine aims to address the prevailing R&D market failure and to assist in the development of medicines that matter to society, for the people that need them most. It is committed to delivering impactful healthcare solutions through developing and executing value focussed drug development programs, business development strategies and technical due diligence. For more information, visit the website at www.d3medicine.com.
About Viroclinics Biosciences BV
Headquartered in Rotterdam, The Netherlands, Viroclinics Biosciences operates at a global level and is the preferred virology testing laboratory for several of the top 10 biopharmaceutical companies. As a virology service organization, the company performs preclinical studies, serves as a central and reference laboratory for phase I-IV clinical trials including high throughput serology-, virology- and molecular assays, assay development services and clinical trial logistics services, involving global logistic support for clinical sample shipment, cold-chain management of the samples and a 24/7 helpdesk in English and Spanish. For more information visit the website at www.viroclinics.com.
Media contacts
d3 Medicine
Dr Leigh Farrell
Chief Operating Officer
T: +61 410 411 662
E: [email protected]
Viroclinics Biosciences
Cindy van Hagen
Director Marketing & Communication
T: +31 88 668 4702
E: [email protected]